Coming Soon? A New Biologic

Coming Soon? A New Biologic

Coming Soon? A New Biologic For the past two decades, monoclonal antibodies (mAbs) have dominated the biologic drugs market. Doctors use these blockbuster products for a range of diseases, including many cancers and autoimmune diseases. In addition to their...
A Bone To Pick With Osteoporosis

A Bone To Pick With Osteoporosis

A Bone To Pick With Osteoporosis Last week, the FDA approved Evenity, Amgen’s (Thousand Oaks, CA) new osteoporosis drug. Heralded as effective at rebuilding bone, the drug promises to be an important weapon in the fight against osteoporosis. Osteoporosis is the loss...
Breaking Down Drug Metabolism

Breaking Down Drug Metabolism

Down the Hatch! Then What? When popping a pill, how often do we think about what happens next—to the pill, or to our bodies? Maybe we assume the body welcomes any extra help to soothe our headache or control our blood pressure. This WEEKLY looks into the mystery of...
On A Tumor’s Turf

On A Tumor’s Turf

On A Tumor’s Turf  Solid tumors are generally considered more difficult to treat than blood cancers. For example, chimeric antigen receptor T-cell (CAR-T) therapy has been amazingly effective against blood cancers that failed to respond to other types of...
Unmasking Multiple Sclerosis

Unmasking Multiple Sclerosis

Multiple SCLEROSIS Awareness March is Multiple Sclerosis (MS) Awareness Month, so this WEEKLY takes a look at the science behind the disease and some of the treatments developed for it. MS typically occurs in susceptible individuals between the ages of 20 and 50, and...